

OCEANARIUM (MAURITIUS) LTD

UNAUDITED CONDENSED FINANCIAL STATEMENTS FOR THE QUARTER ENDED SEPTEMBER 30, 2023

The Directors are pleased to present the unaudited condensed Financial Statements of the Company for the quarter ended September 30, 2023.

1. CONDENSED STATEMENT OF FINANCIAL POSITION

ASSETS

Non-current assets Current assets

Total assets

EQUITY AND LIABILITIES

Equity and reservesEquity holders' interests **Total equity and reserves**

Non-current liabilities

Total equity and liabilities

THE COMPANY		
Unaudited	Audited	
as at	as at	
Sep 30,	Jun 30,	
2023	2023	
Rs'000	Rs'000	
736,463	743,461	
24,374	25,041	
760,837	768,502	
541,537	549,845	
541,537	549,845	
170,886 170,05		
48,414	48,601	
760,837	768,502	

2. CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

Operating (Loss) /Profit before taxation

Net finance costs

(Loss) /Profit before taxation

Taxation

(Loss)/ Profit for the period

Other comprehensive income for the year net of tax

Total comprehensive (loss) / income for the period

Number of ordinary shares ('000)

- In issu

(Loss)/ Profit per share (Rs.) Net Asset Value per share (Rs.)

Unaudited - quarter to			
Sep 30, 2023 Rs'000	Sep 30, 2022 Rs'000		
29,498	33,369		
(7,107)	2,513		
(2,902)	(2,393)		
(10,009)	120		
1,702	(20)		
(8,307)	99		
	-		
(8,307)	99		

57,300

(0.14)

9.45

57,300

0.00

9.60

THE COMPANY

3. CONDENSED STATEMENT OF CASH FLOWS

Net cash (used in)/from operating activities Net cash used in investing activities Net cash generated from financing activities

Decrease in cash and cash equivalents

Opening cash and cash equivalents at July 1, Decrease Net foreign exchange loss

At September 30,

200.00	COL	IPANY
100	CON	IPANI

Unaudited - quarter to		
Sep 30, 2023 Rs'000	Sep 30, 2022 Rs'000	
(1,656) (24,154) 23,736	931 (2,929) 1,590	
(2,074)	(408)	
3,975 (2,074) (64)	3,958 (408)	
1,837	3,550	

4. CONDENSED STATEMENT OF

At July 1, 2023

Loss for the period

Issue of shares

Other comprehensive income for the period $% \left\{ \left(1\right) \right\} =\left\{ \left(1\right) \right\}$

At September 30, 2023

At July 1, 2022

Profit for the period

Issue of shares

Other comprehensive income for the period

At September 30, 2022

THE CONFANT				
Share Capital	Revaluation and other Reserves	Retained Earnings	Total	
Rs'000	Rs'000	Rs'000	Rs'000	
528,000	59,174	(37,329)	549,845	
-	-	(8,307)	(8,307)	
-			-	
-		-	-	
528,000	59,174	(45,636)	541,537	
528,000	550	(6,179)	522,372	
-	-	99	99	
	-	-	-	
-		-	-	
528,000	550	(6,079)	522,471	

NOTES

The unaudited interim quarterly condensed financial statements are in compliance with International Financial Reporting Standards (IFRS) and have been prepared on the same basis as the accounting policies set out in the statutory financial statements of the Company for the year ended June 30, 2023, except for the adoption of published Standards and any amendments and Interpretations issued now effective. This communiqué is issued pursuant to DEM Rule 17 and the Securities Act 2005.

RESULTS & PROSPECTS

Turnover for the quarter ending September 2023 is lower than last year, primarily due to a decrease in local visitors, which can be attributed to the reduced duration of school holidays.

However, the increase in non-resident visitors compared to the previous quarter is a positive indicator of our expanding reach in the tourism market. The upcoming festive season and school holidays are expected to boost both resident and non-resident visits.

By order of the Board

Eclosia Secretarial Services Ltd Secretary

Date: November 10, 2023

Copies of the condensed financial statements and the statement of direct and indirect interests of officers of the Company (required under rule 8(2) (m) of the Securities (Disclosure Obligations of Reporting Issuers) Rules 2007), are available free of charge, upon request made to the Company Secretary, Eclosia Group Headquarters, Gentilly, Moka, Mauritius.

The Board of Directors of Oceanarium (Mauritius) Ltd accepts full responsibility for the accuracy of the information contained in this report.

BRN: C16141503